Citius Pharmaceuticals Inc
Research Citius Pharmaceuticals Inc (CTXR) on Bullrun: market cap USD 16.58M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCTXR
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 16.58M
- Financial periodQ1 2026
- RevenueUSD 1.67M
- Net income-USD 21.23M
- Free cash flow-USD 31.60M
- Gross margin80.3%
Valuation Snapshot
latest market cap is USD 16.58M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 3.94M | -USD 39.74M | -USD 34.84M | n/a | -3.38 | USD 4.25M | USD 1.83M | USD 67.55M |
| FY2024 | USD 0 | -USD 39.43M | -USD 26.79M | n/a | -5.97 | USD 3.25M | USD 204.57K | USD 70.08M |
| FY2023 | n/a | -USD 32.54M | n/a | n/a | -5.57 | USD 26.48M | USD 428.57K | USD 90.83M |
| FY2022 | USD 90.00K | -USD 33.64M | n/a | n/a | -0.23 | USD 41.71M | USD 630.75K | USD 102.83M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 16.58M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 17.45M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 30.91M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 120.31M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 115.51M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 224.89M | n/a | n/a | n/a |
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Citius Pharmaceuticals Inc's market cap?
Citius Pharmaceuticals Inc's market capitalization is USD 16.58M.
What does Citius Pharmaceuticals Inc do?
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.